Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma.

@article{Rosenblatt2011VaccinationWD,
  title={Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma.},
  author={Jacalyn M Rosenblatt and Baldev Vasir and Lynne Uhl and Simona Blotta and Claire Macnamara and Poorvi Somaiya and Zekui Wu and Robin Joyce and James D. Levine and Dilani Dombagoda and Yan Emily Yuan and Karen Francoeur and Donna Fitzgerald and Paul Richardson and Edie Weller and Kenneth A. Anderson and Donald Kufe and Nikhil C. Munshi and David Avigan},
  journal={Blood},
  year={2011},
  volume={117 2},
  pages={393-402}
}
We have developed a tumor vaccine in which patient-derived myeloma cells are chemically fused with autologous dendritic cells (DCs) such that a broad spectrum of myeloma-associated antigens are presented in the context of DC-mediated costimulation. We have completed a phase 1 study in which patients with multiple myeloma underwent serial vaccination with the DC/multiple myeloma fusions in conjunction with granulocyte-macrophage colony-stimulating factor. DCs were generated from adherent… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 87 extracted citations

Targeting Multiple-Myeloma-Induced Immune Dysfunction to Improve Immunotherapy Outcomes

Clinical & developmental immunology • 2012
View 4 Excerpts
Highly Influenced

Cellular immunotherapy using dendritic cells against multiple myeloma

The Korean journal of hematology • 2012
View 4 Excerpts
Highly Influenced

References

Publications referenced by this paper.
Showing 1-10 of 49 references

NY-ESO-1 is highly expressed in poor-prognosis DC/MYELOMA FUSION VACCINE INDUCES IMMUNE RESPONSES 401 BLOOD

F van Rhee, SM Szmania, F Zhan
NUMBER 2 For personal use only. on April • 2011

Similar Papers

Loading similar papers…